• Explore /
  • Poster
  • / Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: A multicenter randomized trial, CROSS-J-RCC.

Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: A multicenter randomized trial, CROSS-J-RCC.

Abstract Poster

Authors

null

Yoshihiko Tomita

Department of Urology, Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Yoshihiko Tomita , Sei Naito , Naoto Sassa , Atsushi Takahashi , Tsunenori Kondo , Takuya Koie , Wataru Obara , Yasuyuki Kobayashi , Jun Teishima , Masayuki Takahashi , Hideyasu Matsuyama , Takeshi Ueda , Kenya Yamaguchi , Takeshi Kishida , Ryoichi Shiroki , Takashi Saika , Nobuo Shinohara , Mototsugu Oya , Hiroomi Kanayama

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer

Track

Renal Cell Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

01481870

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 469)

DOI

10.1200/JCO.2017.35.6_suppl.469

Abstract #

469

Poster Bd #

E8

Abstract Disclosures

Similar Posters

First Author: Camila Nassif Martins Ferreira

First Author: John D. Hainsworth

First Author: Daniele Santini

First Author: Nizar M. Tannir